Plaguing humans for more than two millennia, manifest on every continent studied, and with
more than one billion patients having an attack in any year, migraine stands as the sixth …

Migraine can be regarded as a conserved, adaptive response that occurs in genetically
predisposed individuals with a mismatch between the brain's energy reserve and workload …

The cytochrome p450 enzyme, CYP2D6, metabolises approximately 20% of marketed
drugs. CYP2D6 multiple variants are associated with altered enzyme activities. Genotyping …

Despite that it is commonly accepted that migraine is a disorder of the nervous system with a
prominent genetic basis, it is comorbid with a plethora of medical conditions. Several studies …

Chronic pain conditions are multifactorial disorders with a high frequency in the population.
Their pathophysiology is often unclear, and treatment is inefficient. During the last 20 years …

In two randomly selected human genomes, 99.9% of the DNA sequence is identical. The
remaining 0.1% of DNA contains sequence variations. The most common type of such …

The D2 dopamine receptor (DRD2) has been one of the most extensively investigated gene
in neuropsychiatric disorders. After the first association of the TaqI A DRD2 minor (A1) allele …

Genotyping data sets may contain errors that, in some instances, lead to false conclusions.
Deviation from Hardy–Weinberg equilibrium (HWE) in random samples may be indicative of …

Migraine is an episodic neurovascular disorder that is clinically divided into two main
subtypes that are based on the absence or presence of an aura: migraine without aura (MO) …

Pharmacogenetics provides opportunities for informed decision-making along the
pharmaceutical pipeline. There is a growing literature of retrospective studies of marketed …